ERAS
Price
$9.55
Change
+$1.25 (+15.04%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
2.36B
63 days until earnings call
Intraday BUY SELL Signals
IMUX
Price
$0.64
Change
-$0.01 (-1.54%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
78.19M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs IMUX

Header iconERAS vs IMUX Comparison
Open Charts ERAS vs IMUXBanner chart's image
Erasca
Price$9.55
Change+$1.25 (+15.04%)
Volume$128.98K
Capitalization2.36B
Immunic
Price$0.64
Change-$0.01 (-1.54%)
Volume$16.67K
Capitalization78.19M
ERAS vs IMUX Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
IMUX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. IMUX commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and IMUX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ERAS: $8.31 vs. IMUX: $0.65)
Brand notoriety: ERAS and IMUX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 269% vs. IMUX: 123%
Market capitalization -- ERAS: $2.36B vs. IMUX: $78.19M
ERAS [@Biotechnology] is valued at $2.36B. IMUX’s [@Biotechnology] market capitalization is $78.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileIMUX’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • IMUX’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than IMUX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 4 TA indicator(s) are bullish while IMUX’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 4 bullish, 4 bearish.
  • IMUX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than IMUX.

Price Growth

ERAS (@Biotechnology) experienced а +60.74% price change this week, while IMUX (@Biotechnology) price change was -5.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.23%. For the same industry, the average monthly price growth was +2.54%, and the average quarterly price growth was +43.40%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

IMUX is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (-0.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($2.36B) has a higher market cap than IMUX($78.2M). ERAS YTD gains are higher at: 123.387 vs. IMUX (21.791). IMUX has higher annual earnings (EBITDA): -105.37M vs. ERAS (-131.32M). ERAS has more cash in the bank: 288M vs. IMUX (35.1M). IMUX has less debt than ERAS: IMUX (792K) vs ERAS (48.3M). ERAS (0) and IMUX (0) have equivalent revenues.
ERASIMUXERAS / IMUX
Capitalization2.36B78.2M3,018%
EBITDA-131.32M-105.37M125%
Gain YTD123.38721.791566%
P/E RatioN/AN/A-
Revenue00-
Total Cash288M35.1M821%
Total Debt48.3M792K6,098%
FUNDAMENTALS RATINGS
IMUX: Fundamental Ratings
IMUX
OUTLOOK RATING
1..100
5
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
36

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASIMUX
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
87%
Bearish Trend 17 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
IMUX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RRRRX21.580.19
+0.89%
DWS RREEF Real Estate Securities Instl
JERCX12.070.06
+0.50%
Janus Henderson Global Real Estate C
SEKCX21.300.06
+0.28%
DWS Emerging Markets Equity C
MDLOX20.53-0.05
-0.24%
BlackRock Global Allocation Inv A
IDVSX28.50-0.19
-0.66%
Morgan Stanley Inst Intl Advtg R6

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+10.73%
RVMD - ERAS
61%
Loosely correlated
+1.06%
NUVL - ERAS
48%
Loosely correlated
+6.59%
ZNTL - ERAS
47%
Loosely correlated
+0.86%
CRNX - ERAS
47%
Loosely correlated
+2.04%
XNCR - ERAS
45%
Loosely correlated
+3.66%
More

IMUX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with PLRX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
-4.03%
PLRX - IMUX
36%
Loosely correlated
+1.55%
ERAS - IMUX
35%
Loosely correlated
+10.73%
ORIC - IMUX
34%
Loosely correlated
+10.95%
REVB - IMUX
30%
Poorly correlated
-0.57%
ENSC - IMUX
29%
Poorly correlated
+0.50%
More